Core Insights - The 2025 Innovation Drug High-Quality Development Conference was held in Guangzhou, announcing the new drug directories for national basic medical insurance and commercial health insurance [1] Group 1: Drug Directory Adjustments - A total of 114 new drugs were added to the directory, including 50 first-class innovative drugs [2][6] - The first version of the commercial health insurance innovative drug directory includes 19 drugs, featuring CAR-T therapies for tumors, treatments for rare diseases like neuroblastoma and Gaucher disease, and Alzheimer's disease medications [2][4] Group 2: Complementarity of Insurance Directories - The commercial health insurance innovative drug directory is designed to complement the basic medical insurance, focusing on high-innovation drugs with significant clinical value that exceed basic insurance coverage [4] - The directory aims to clarify the boundaries of basic medical insurance and promote the development of a multi-tiered medical security system [4] Group 3: Financial Implications for Patients - The inclusion of CAR-T therapies, which can cost around 1.2 million yuan per treatment, is expected to significantly reduce out-of-pocket expenses for patients, potentially saving them hundreds of thousands of yuan [5] Group 4: Implementation Timeline - The new drug directory adjustments will be officially implemented nationwide on January 1, 2026, marking the eighth adjustment since the establishment of the National Medical Insurance Administration [6][7]

Core Insights - The annual adjustment of the National Medical Insurance Drug List has significant implications for public health and access to medications, with 114 new drugs added to the insurance coverage and 19 new drugs included in the commercial insurance innovation drug list [1][2]. Group 1: Drug List Adjustments - A total of 114 drugs have been added to the National Medical Insurance Drug List, including 36 cancer drugs, 12 diabetes medications, 13 anti-infective drugs, and 10 rare disease treatments [2]. - The new list includes essential drugs that fill gaps in basic medical insurance, such as drugs for triple-negative breast cancer and pancreatic cancer, which are critical for patient survival [2]. - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. Group 2: Commercial Insurance Innovation Drug List - The commercial insurance innovation drug list includes 19 new drugs focusing on high innovation and significant clinical value, such as CAR-T therapies and treatments for rare diseases [3]. - The new policy allows for "three exclusions" for drugs in the commercial insurance innovation list, facilitating patient access to urgently needed medications [3]. Group 3: Market Impact and Future Outlook - The inclusion of high-cost innovative drugs in the commercial insurance list is expected to benefit more patients and encourage pharmaceutical companies to invest in research and development [4]. - Over the past eight years, the National Medical Insurance Drug List has added 949 drugs, with insurance expenditures reaching 460 billion yuan, significantly boosting the pharmaceutical market [5]. - The approval of 69 innovative drugs in 2025 and over 100 overseas authorizations exceeding 100 billion yuan indicates a rapid acceleration in the innovation drug sector in China [5].

Group 1 - The company announced that its product, Sidabenamine tablets (Epidaza), has been included in the National Medical Insurance Directory under regular Class B management, effective January 1, 2026 [1][3] - The inclusion of Sidabenamine in the National Medical Insurance Directory is expected to enhance patient access to medication and stabilize the pricing system for innovative drugs [3] - The product is classified under the insurance payment scope for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and for untreated diffuse large B-cell lymphoma (DLBCL) patients when used in combination with R-CHOP [1][2] Group 2 - Sidabenamine is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and has been approved for various cancers in different regions, including PTCL and DLBCL in mainland China, and adult T-cell leukemia in Japan [2] - The company has pioneered the licensing of innovative drugs from China to Europe and the United States, marking a significant milestone in the industry [2]

Core Insights - The 2025 National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory were announced, marking a significant development in the pharmaceutical industry [1][3][10] - A total of 114 new drugs were added to the National Medical Insurance Directory, including 50 innovative drugs, which is expected to enhance patient access and support sustainable investment in drug development [1][2][3] National Medical Insurance Directory - The 2025 National Medical Insurance Directory includes 114 new drugs, with 50 classified as innovative drugs, such as Tislelizumab and domestic ADC drugs [1][3] - Companies like Kelun-Biotech and Kangnuo have successfully included their innovative drugs in the directory, reflecting strong government support for domestic innovation [3][4] - The total number of drugs in the National Medical Insurance Directory has increased to 3,253, with significant improvements in coverage for critical areas like oncology and chronic diseases [5][6] Commercial Health Insurance Innovative Drug Directory - The newly introduced Commercial Health Insurance Innovative Drug Directory includes five CAR-T cell therapies and several high-cost drugs for rare diseases, enhancing accessibility for patients [1][6][8] - The directory allows innovative drug companies to explore new payment channels outside of traditional medical insurance, potentially increasing patient access to high-value therapies [11][12] - The pricing for drugs in the Commercial Health Insurance Directory is expected to be more flexible, allowing for negotiations between companies and insurers, which could lead to better affordability for patients [8][12] Industry Impact - The introduction of the Commercial Health Insurance Innovative Drug Directory is seen as a milestone for improving drug accessibility and affordability, particularly for high-cost therapies [7][9][12] - The past decade has witnessed significant growth in China's innovative drug sector, with the new directory marking a pivotal moment in the industry's evolution [10][11] - The dual-track payment framework established by the National Medical Insurance and Commercial Health Insurance is expected to foster a more robust ecosystem for drug research and application in China [12]

Core Viewpoint - The company Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales potential for the product [1][2]. Group 1: Product Information - Angladiwei Tablets are the world's first targeted drug for the PB2 subunit of the influenza A virus RNA polymerase, approved for treating adult patients with uncomplicated influenza [2]. - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a cost-effective and accessible treatment option for patients [2]. Group 2: Market Impact - The inclusion of Angladiwei Tablets in the National Medical Insurance Directory is anticipated to positively impact the company's long-term operational development and market presence [2]. - Other core products of the company, including Lai Ru Te Wei Tablets and various other formulations, continue to be listed in the National Medical Insurance Directory, supporting the company's overall product portfolio [1].

证券代码：688321 证券简称：微芯生物 公告编号：2025-082 深圳微芯生物科技股份有限公司 自愿披露关于公司产品纳入国家医保目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 2025年12月7日，根据国家医保局、人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生 育保险药品目录》（以下简称"《国家医保目录》"）以及《商业健康保险创新药品目录》（2025年）的 通知【医保发〔2025〕33号】。深圳微芯生物科技股份有限公司（以下简称"公司"）产品西达本胺片 （爱谱沙?）纳入《国家医保目录》常规乙类管理。现将相关信息公告如下： 医保支付范围：1.既往至少接受过一次全身化疗的复发或难治的外周T细胞淋巴瘤(PTCL)患者；2.联合 R-CHOP(利妥昔单抗、环磷酰胺、阿霉素、长春新碱和强的松)用于MYC和BCL2表达阳性的既往未经 治疗的弥漫大B细胞淋巴瘤(DLBCL)患者。 二、药品相关情况 西达本胺（商品名"爱谱沙?/Epidaza?"）是全球首个亚型选择性组蛋白去乙酰化酶（HDAC）抑制剂， 开创 ...

Core Insights - The release of the "dual directories" marks a significant step in building a multi-tiered medical insurance system and supporting the development of innovative drug industries in China [1] Group 1: Medical Insurance Coverage - The adjusted national medical insurance drug directory now includes a total of 3,253 drugs, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2] - The 2025 national medical insurance drug directory includes drugs that fill gaps in basic medical insurance coverage, addressing major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions [2] - Notable companies like Innovent Biologics and Jiangsu Hengrui Medicine have multiple products included in the 2025 national medical insurance drug directory, covering various therapeutic areas [2] Group 2: Commercial Health Insurance - The first edition of the "Commercial Health Insurance Innovative Drug Directory" focuses on high-innovation drugs that provide significant clinical value but are currently too expensive for basic medical insurance coverage [2][3] - A total of 19 drugs have been included in this directory, including cutting-edge treatments for cancer and rare diseases, as well as Alzheimer's disease [3] Group 3: Policy and Capital Resonance - Recent policies have optimized medical insurance spending and structure, increasing support for innovative drugs and medical devices [4] - Over the past seven years, 835 drugs have been newly included in the medical insurance payment scope, with 149 of them being innovative drugs [4] - The introduction of the commercial health insurance innovative drug directory is seen as a crucial measure to address payment challenges and promote the development of truly clinically valuable drugs [4] Group 4: Industry Outlook - The pharmaceutical industry is expected to enter a new phase of policy stabilization, industrial upgrading, and internationalization over the next five years [5] - The convergence of demand, policy, and supply is anticipated to enhance the prosperity of the pharmaceutical sector [5]

Core Insights - The article emphasizes the development of emerging pillar industries and strategic emerging industry clusters such as new energy, new materials, aerospace, and low-altitude economy, which are expected to create several trillion-yuan markets [1][9]. - It also highlights the forward-looking layout of future industries, promoting quantum technology, biomanufacturing, hydrogen energy, nuclear fusion energy, brain-computer interfaces, embodied intelligence, and sixth-generation mobile communication as new economic growth points, with the potential to recreate a high-tech industry equivalent to another China in the next decade [1][9]. Group 1: Future Industries Overview - Future industries include six major focus areas and ten innovative flagship products, which are crucial for investment direction [2]. - The article outlines four key directions for capital market focus during the 14th Five-Year Plan period: future information, future space and security, future energy, and future health [10]. Group 2: Strategic Emerging Industries - The article discusses the acceleration of strategic emerging industries such as new generation information technology, biotechnology, new energy, new materials, high-end equipment, new energy vehicles, green environmental protection, and aerospace [6]. - It emphasizes the integration of the internet, big data, and artificial intelligence with various industries to foster advanced manufacturing clusters and cultivate new technologies, products, business formats, and models [6]. Group 3: Investment Opportunities - The article identifies ten major investment opportunities, including AI, aerospace, and renewable energy, with specific focus on the development of advanced materials, quantum information, integrated circuits, and intelligent manufacturing technologies [5][14]. - It highlights the importance of the aerospace sector, noting the increasing strategic layout in both China and the US, with initiatives aimed at enhancing commercial aerospace development and reducing regulatory barriers [14][16]. Group 4: Nuclear Fusion and Energy - The article discusses the potential of controlled nuclear fusion as a future energy source, outlining the industry chain that supports its commercialization, including upstream raw materials, midstream equipment manufacturing, and downstream power generation [29][31]. - It contrasts nuclear fusion with nuclear fission, highlighting the safety, sustainability, and environmental advantages of fusion energy [33][35].

Core Insights - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog and the first Commercial Health Insurance Innovative Drug Catalog were officially released on December 7, highlighting significant advancements in drug accessibility and innovation support [1][6]. Summary by Sections Basic Medical Insurance Drug Catalog - A total of 114 new drugs were added, with 50 being first-class innovative drugs, achieving an overall success rate of 88%, an increase from 76% in 2024 [3][5]. - The total number of drugs in the National Medical Insurance Drug Catalog has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines, with enhanced coverage for critical areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [3][5]. - The new drug catalog will be implemented starting January 1, 2026, with a six-month transition period for drugs that were not successfully renewed [3][4]. Commercial Health Insurance Innovative Drug Catalog - The Commercial Health Insurance Innovative Drug Catalog includes 19 drugs from 18 innovative pharmaceutical companies, focusing on high clinical value and innovation, particularly in cancer, rare diseases, and chronic conditions [7][9]. - The catalog emphasizes three main characteristics: support for innovation, focus on key therapeutic areas, and a clear distinction between basic medical insurance and commercial insurance coverage [7][9]. - Notable inclusions are five CAR-T products and new treatments for Alzheimer's disease and Gaucher disease, reflecting a trend towards covering high-cost, innovative therapies through commercial insurance [8][9]. Innovation and Market Impact - The inclusion of a significant number of first-class innovative drugs in the basic medical insurance catalog demonstrates the government's commitment to enhancing drug accessibility and encouraging pharmaceutical innovation [6][9]. - The successful negotiation rates and the focus on innovative drugs in both catalogs are expected to stimulate further investment in drug research and development by pharmaceutical companies [6][9].

Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the Commercial Health Insurance Innovative Drug Catalog for 2025, which includes 114 new drugs, 50 of which are Class 1 innovative drugs [1] - The total number of drugs in the National Medical Insurance Drug Catalog will increase to 3,253, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] - The introduction of the Commercial Health Insurance Innovative Drug Catalog is expected to alleviate payment challenges for high-value innovative drugs, providing an additional payment pathway beyond basic medical insurance [1] Group 2 - Zai Lab is in a rapid product expansion phase, with a rich pipeline of projects, and its clinical development of ZG006 is among the global leaders, potentially becoming the best in its class [2] - Zai Lab's self-developed drug, Jikangxi (sodium gikaxtin), has been included in the National Medical Insurance Drug Catalog following negotiations [2] - Junshi Biosciences has four commercialized products included in the 2025 National Medical Insurance Drug Catalog, with two new indications for Tuoyi (Tremelimumab) successfully added, and Junshida (Ongentys) being included for the first time [2]